血脂泰分散片Ⅰ期临床人体耐受性研究

目的：考察健康人对不同剂量血脂泰分散片的耐受性和安全性,为制定血脂泰分散片Ⅱ期临床试验给药方案提供安全的剂量范围。方法：将筛选合格的40例健康受试者,采用开放、随机、多剂量组及自身前后对照设计,按顺序进行血脂泰分散片单次给药和连续给药耐受性试验。单次给药组受试者共28例,分为5个剂量组,给药剂量分别为4、6、8、10及12片（有效部位含量为20 mg/片）,1日给药1次;多次给药组受试者共12例,分为2个剂量组,给药剂量分别为10、12片,1日给药1次,连续7 d。观察指标为生命体征、理化检查、不良反应。应用SAS软件进行统计分析。结果：单次给药组和多次给药组均有1例受试者发生腹泻不良反应,其...

Full description

Saved in:
Bibliographic Details
Published in中国医院用药评价与分析 Vol. 17; no. 11; pp. 1460 - 1463
Main Author 周翠兰;胡思源;倪天庆;黄大森;张广明
Format Journal Article
LanguageChinese
Published 广州一品红制药有限公司研发中心,广东广州,510760%天津中医药大学第一附属医院儿科,天津,300193 2017
Subjects
期临床
耐受性
血脂泰分散片
血脂泰分散片
Tolerance
期临床
耐受性
Xuezhitai dispersible tablets
Phase Ⅰ clinical trial
Online AccessGet full text
ISSN1672-2124
DOI10.14009/j.issn.1672-2124.2017.11.006

Cover

More Information
Summary:目的：考察健康人对不同剂量血脂泰分散片的耐受性和安全性,为制定血脂泰分散片Ⅱ期临床试验给药方案提供安全的剂量范围。方法：将筛选合格的40例健康受试者,采用开放、随机、多剂量组及自身前后对照设计,按顺序进行血脂泰分散片单次给药和连续给药耐受性试验。单次给药组受试者共28例,分为5个剂量组,给药剂量分别为4、6、8、10及12片（有效部位含量为20 mg/片）,1日给药1次;多次给药组受试者共12例,分为2个剂量组,给药剂量分别为10、12片,1日给药1次,连续7 d。观察指标为生命体征、理化检查、不良反应。应用SAS软件进行统计分析。结果：单次给药组和多次给药组均有1例受试者发生腹泻不良反应,其他生命体征及实验室检查未见与药物有关的具有临床意义的变化。结论：血脂泰分散片单次给药≤12片;或剂量≤1次12片,1日1次,连续给药7 d,在人体的应用是安全的。
Bibliography:Xuezhitai dispersible tablets; Phase I clinical trial; Tolerance
OBJECTIVE： To investigate the tolerance and safety of different dose of Xuezhitai dispersible tablets on human body,so as to provide safe dosage range of formulation of Xuezhitai dispersible tablets in phase Ⅱ clinical trials. METHODS： The opened,randomized,multi-doses,self-controlled design was adopted, single dose and continuous administration tolerance test of Xuezhitai dispersible tablets were conducted on 40 healthy volunteers. Single dose group was 28 cases,totally 5 dose groups,with administration of 4 tablets,6 tablets,8 tablets,10 tablets and 12 tablets（ the effective site content is 20 mg per tablet）,qd. And continuous administration group was 12 healthy volunteers,totally 2 dose groups,with administration of 10 and 12 tablets,qd,for 7 days. The observation indicators were respectively vital signs,physical and chemical inspection and adverse drug reactions. Statistical analysis was conducted by using SAS software. RESULTS： One case of d
ISSN:1672-2124
DOI:10.14009/j.issn.1672-2124.2017.11.006